SEQUENCE LISTING

<110> Roche Diagnostics GmbH
F. Hoffmann-La Roche AG

<120> Improved method for bisulfite treatment

<130> 21581 WO

<140>
<141>

<150> EP03001854.3
<151> 2003-01-29

<150> EP03010020.0
<151> 2003-05-02

<160> 8

<170> PatentIn Ver. 2.1

<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:sense strand

<400> 1
gaggggcgcc ctggagtccc 20

<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:antisense strand

<400> 2
gggactccag ggcgcccctc 20

<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:sense strand, c converted to n, n denotes deoxyuracil

<400> 3
gaggggngnn ntggagtnnn 20

<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:antisense strand, c converted to n, n denotes deoxyuracil

<400> 4
gggantnnag ggngnnnntn 20

<210> 5
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:synthesized oligonucleotide

<400> 5
ttttttcttt t 11

<210> 6
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:synthesized oligonucleotide, c in position 6 is methylated

<400> 6
ttttttcttt t 11

<210> 7
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:synthesized oligonucleotide, c converted to n, n denotes deoxyuracil

<400> 7
ttttttnttt t 11

<210> 8
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:synthesized oligonucleotide

<400> 8
ttttttttt t 11